Oncological and functional outcomes of transanal total mesorectal excision in a teaching hospital in the Netherlands
10.3393/ac.2020.00773.0110
- Author:
Joost A.G. VAN DER HEIJDEN
1
;
Kelly G.H. VAN DE PAS
;
Frank J.C. VAN DEN BROEK
;
Francois M.H. VAN DIELEN
;
Gerrit D. SLOOTER
;
Adriana J.G. MAASKANT-BRAAT
Author Information
1. Department of Surgery, Máxima Medical Centre, Veldhoven, the Netherlands
- Publication Type:Original Article
- From:Annals of Coloproctology
2022;38(1):28-35
- CountryRepublic of Korea
- Language:English
-
Abstract:
Purpose:Transanal total mesorectal excision (TaTME) was developed to overcome surgical difficulties experienced in distal pelvic dissection. Concerns have been raised about potential worse postoperative functional outcomes after TaTME. Also, the oncological safety was questioned. This study aimed to describe the functional, surgical, oncological outcomes and quality of life (QoL) after TaTME.
Methods:All consecutive TaTME cases for rectal cancer without disseminated disease between December 2016 and April 2019 were included. The Wexner incontinence score, low anterior resection syndrome (LARS) score, fecal incontinence-related QoL, and the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-core questionnaire and 29-item module (EORTC QLQ-C30/CR29) were collected. Kaplan-Meier analysis was used to calculate local recurrence-free survival.
Results:Thirty patients were eligible for analysis of which 23 received questionnaires. Response rate was 74%. After a median follow-up of respectively 20.0 and 23.0 months for functional and oncological outcomes, the median (interquartile range) of Wexner incontinence and LARS scores were 9.0 (7.0–12.0) and 33.1 (25.0–39.0). Major LARS was present in 73.3%. Fecal incontinence, general and colorectal-specific QoL subdomains that are associated with poor bowel function scored in line with previously reported data. The 2-year actuarial cumulative local recurrence rate was 3.7% (95% confidence interval, 2.4%–5.0%).
Conclusion:TaTME may lead to significant functional impairments. Patients should receive preoperative counseling on this topic and be fully aware of the potential consequences of their treatment. Oncological data were in line with other short- to moderate-term data and did not show alarming results.
